期刊文献+

稳定表达烟酸受体GPR109A的中国仓鼠卵巢细胞株的建立

Establishment of a Chinese Hamster Ovary Cell Line Stably Expressing Nicotinic Acid Receptor GPR109A
下载PDF
导出
摘要 目的将GPR109A基因插入pEGFP-N3载体中构建重组质粒pEGFP-GPR109A,并建立稳定表达烟酸受体GPR109A的中国仓鼠卵巢(Ch inese ham ster ovary,CHO)细胞株。方法构建重组质粒pEGFP-GPR109A,重组质粒转化大肠杆菌DH5 a,重组质粒经PCR、酶切、测序验证正确后,应用脂质体转染技术将该质粒导入CHO细胞,用抗生素G418筛选稳定表达的细胞。倒置荧光显微镜观察克隆细胞株荧光信号,RT-PCR检测GPR109A基因mRNA表达,W estern B lotting检测绿色荧光蛋白与烟酸受体GPR109A的融合蛋白(GFP-GPR109A)的表达,激光共聚焦显微镜观察融合蛋白的细胞定位。结果 pEGFP-GPR109A真核表达质粒构建正确,融合蛋白GFP-GPR109A在CHO细胞中稳定表达,表达的融合蛋白主要定位于细胞膜。结论成功构建pEGFP-GPR109A真核表达载体并建立其稳定表达的CHO细胞株;该细胞株的建立有助于GPR109A的更多生理病理功能研究,也为下一步抗动脉粥样硬化的药物筛选奠定了基础。 Aim To construct pEGFP-GPR109A recombinant plasmid by inserting GPR109A gene into pEGFP-N3 vector and establish a Chinese hamster ovary(CHO)cell line stably expressing nicotinic acid receptor GPR109A. Methods The pEGFP-GPR109A recombinant plasmid was constructed,which was subsequently transformed into DH5α E coli.After identification by PCR,digestion with restriction endonuclease and sequencing,the recombinant plasmid was transfected into CHO cells via lipofectamine 2000.The stable transfectants were screened by antibiotic G418.The fluorescent signal of cloned cell lines were detected by fluorescent microscope.The GPR109A gene mRNA expression was analyzed by RT-PCR and the fusion protein expression of green fluorescence protein and nicotinic acid receptor GPR109A(GFP-GPR109A) was detected by Western Blotting.The cell localization of fusion protein was detected by laser scanning confocal microscope. Results The results of PCR,restriction endonuclease digestion and sequencing all confirmed the correct construction of the recombinant eukaryotic expression plasmid pEGFP-GPR109A.Western Blotting showed that the fusion protein GFP-GPR109A was expressed stably in CHO cells.The fusion protein was mainly localized on cell membrane detected by laser scanning confocal microscope. Conclusion The eukaryotic expression vector pEGFP-GPR109A has been successfully constructed and a CHO cell line stably expressing fusion protein GFP-GPR109A was established,which facilitated the physiological and pathological function research of GPR109A and also provided important foundation for following up drug screening for atherosclerosis treatment.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2011年第4期305-309,共5页 Chinese Journal of Arteriosclerosis
关键词 烟酸受体 真核表达载体 分子克隆 中国仓鼠卵巢细胞 Nicotinic Acid Receptor Eukaryotic Expression Vectors Molecular Cloning Chinese Hamster Ovary Cells
  • 相关文献

参考文献11

  • 1Carlson L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review[J]. J Int Med, 2005, 258(2) : 94.
  • 2赵水平.烟酸类调脂药物研究进展[J].临床药物治疗杂志,2010,8(2):5-8. 被引量:14
  • 3Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect[J]. Nat Med, 2003, 9(3) : 352-355.
  • 4程洁,吕宝经,郑宏超,徐伟平,张亚臣.颈动脉粥样硬化与冠状动脉狭窄程度的关系[J].中国动脉硬化杂志,2004,12(1):65-68. 被引量:81
  • 5Libby P. Inflammation in atherosclerosis [ J]. Nature, 2002, 420(6917) : 868-874.
  • 6徐也鲁.动脉粥样硬化——一种慢性炎症过程[J].中国动脉硬化杂志,2001,9(2):93-95. 被引量:187
  • 7Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: phar- macological effects and mechanisms of action [ J ]. Annu Rev Pharmacol Toxicol, 2008, 48: 79-106.
  • 8Kamanna VS, Kashyap ML. Mechanism of action of niacin [J]. Am J Cardiol, 200S, 101(S) : S20-S26.
  • 9Boatman P, Richman J, Semple G. Nicotinic acid receptor agonists[J]. J Med Chem, 2008, 51(24) : 7 653-662.
  • 10Bodor E, Offermanns S. Nicotinic acid: an old drug with a promising future [ J ]. Brit J Pharmacol, 2008, 153 ( S1 ) : S68-S75.

二级参考文献28

  • 1Anja Vogt, Ursula Kassner, Ulrike Hostalek, et al. Prolonged - release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study [ J ]. vascular health and risk management ,2007,3 ( 4 ) :467- 479.
  • 2Goldberg A, Alagona PJ, Capuzzi DM, et al. Multiple - dose efficacy and safety of an extended - release form of niacin in the management of hyperlipidemia [ J ]. Am J Cardiol,2000,85 (9) : 1100- 1105.
  • 3Guyton JR, Blazing MA, Hagar J, et al. Extended - release niacin vs. gemfibrozil for the treatment of low levels of high - density lipoprotein cholesterol. Niaspan - Gemfibrozil Study Group [ J ]. Arch Intern Med ,2000,160 ( 8 ) : 1177- 1184.
  • 4Birjmohun RS, Hutten BA, Kastelein JJ,et al. Efficacy and safety of high - density lipoprotein cholesterol - increasing compounds : a meta- analysis of randomized controlled trials[J]. J Am Coil Cardiol, 2005,45(2) :185- 197.
  • 5McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia[ J]. Am J Cardiol,2001,88 ( 3 ) :270- 274.
  • 6Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high - density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g) [J]. Am J Cardiol,2008,102(10): 1341-1347.
  • 7Kashyap ML, Mcgovern ME, Berra K, et al. Long - term safety and efficacy of a once - daily niacin/lovastatin formulation for patients with dyslipidemia [ J ]. Am J Cardiol, 2002,89 ( 6 ) : 672- 678.
  • 8Karas RH,Kashyap ML, Knopp RH, et al. Long -term safety and efficacy of a combination of niacin extended release and simvastatin n patients with dyslipidemia: the OCEANS study[J]. Am J Cardiovase Drugs, 2008,8 ( 2 ) : 69- 81.
  • 9McKenney JM ,Jones PH, Bays HE, et al. Comparative effects on lip d levels of combination therapy with a statin and extended - release niacin or ezetimibe versus a statin alone ( the COMPELL study) [ J ]. Atherosclerosis ,2007,192 ( 2 ) :432- 437.
  • 10Peter Alagona Jr. Beyond LDL cholesterol: the role of eievated triglycerides and low HDL cholesterol in residual CVD risk remaining afer statin therapy[ J]. Am J Manag care. 2009,15 :S65- S73.

共引文献279

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部